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Abstract
Objectives To update the 2012 ESGAR consensus guidelines
on the acquisition, interpretation and reporting of magnetic
resonance imaging (MRI) for clinical staging and restaging
of rectal cancer.
Methods Fourteen abdominal imaging experts from the
European Society of Gastrointestinal and Abdominal
Radiology (ESGAR) participated in a consensus meeting,
organised according to an adaptation of the RAND-UCLA
Appropriateness Method. Two independent (non-voting)
Chairs facilitated the meeting. 246 items were scored (com-
prising 229 items from the previous 2012 consensus and 17
additional items) and classified as ‘appropriate’ or
‘inappropriate’ (defined by ≥ 80 % consensus) or uncertain
(defined by < 80 % consensus).
Results Consensus was reached for 226 (92%) of items. From
these recommendations regarding hardware, patient prepara-
tion, imaging sequences and acquisition, criteria for MR im-
aging evaluation and reporting structure were constructed.
The main additions to the 2012 consensus include recommen-
dations regarding use of diffusion-weighted imaging, criteria
for nodal staging and a recommended structured report
template.
Conclusions These updated expert consensus recommenda-
tions should be used as clinical guidelines for primary staging
and restaging of rectal cancer using MRI.
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Key Points
• These guidelines present recommendations for staging and
reporting of rectal cancer.
• The guidelines were constructed through consensus amongst
14 pelvic imaging experts.
• Consensus was reached by the experts for 92 % of the 246
items discussed.
• Practical guidelines for nodal staging are proposed.
• A structured reporting template is presented.
Keywords Magnetic resonance imaging . Cancer rectal
neoplasms . Standards . Staging . Structured reporting
Introduction
In 2012 the European Society of Gastrointestinal and
Abdominal Radiology (ESGAR) initiated an expert con-
sensus meeting on magnetic resonance imaging (MRI)
for the clinical management of rectal cancer, the results
of which were published in European Radiology in
2013 [1]. To update these, 14 abdominal imaging ex-
perts from leading colorectal cancer centres participated
in a formal consensus process aimed at defining a state-
of-the-art MR protocol for rectal cancer and how imag-
ing findings should be interpreted and reported. This
update was precipitated by evolutions in the clinical
management of rectal cancer since the 2012 guideline.
Organ-preserving treatment strategies are used increas-
ingly as alternatives to surgical resection in patients
responding well to chemoradiotherapy (CRT) [2–4].
Accordingly, response assessment after chemoradiother-
apy (CRT) is increasingly relevant and restaging MRI
has become an intense topic for research. Moreover,
functional MR imaging techniques such as diffusion-
weighted imaging (DWI) and dynamic contrast-
enhanced (DCE) MRI are increasingly incorporated into
clinical MRI protocols. This 2016 update aimed to ac-
count for these recent developments. This paper reports
findings from this consensus meeting and aims to
provide up-to-date practice guidelines for MR imaging
acquisition, interpretation and reporting for primary
staging and restaging of rectal cancer.
Materials and methods
The consensus method
Similar to themethodology adopted for the 2012 consensusmeet-
ing [1] an adaptation of the RAND-UCLA Appropriateness
Method (RAM) was chosen [5], which combines postal and
face-to-face rounds. For the present update, the process can be
summarised as follows:
Step 1 Literature review
Two of the organisingmembers (DL,MM) in con-
sensus searched current literature to identify newly
available indexed scientific evidence regarding rectal
cancer imaging, published following the 2012 meet-
ing, which was used to update the questionnaires
used for the 2012 consensus meeting by addition of
topics not discussed previously.
Step 2 Update of the questionnaires
Updated questionnaires were constructed by two
organising members (DL, MM), in consultation with
two others (SB, RB). The original 2012 questionnaire
comprised 236 items. Seventeen new items were
added, which mainly concerned the current use of
tumour node metastasis (TNM) staging systems [6,
7], the staging of tumours extending into the anal
canal, criteria for nodal staging, use of structured
reporting, and protocols for acquisition and evalua-
tion of DWI. The questionnaire was divided into part
A and part B. Part A included items reaching consen-
sus in the 2012 meeting. Panellists were asked to
indicate for each item whether they still agreed with
the consensus statement reached previously or
whether the item should be re-discussed. Part B com-
bined items that did not reach consensus in 2012 with
the additional 17 items derived from the updated lit-
erature review. All items were scored binomial (YES/
NO; still valid or to be rediscussed) or ordinal (e.g.
not recommended, recommended, mandatory), ac-
cording to the individual item in question. Panellists
were instructed to select ‘Mandatory’ for items that
they considered were mandatory, ‘Recommended’
for items that they believed to be of additional benefit
but that were not mandatory, and ‘Not recommended’
for items that they believed were not required and of
no additional value.
Step 3 Panel selection
The panel consisted of the same 14 panellists (BB,
LC-S, HF, MG, SG, SH, CH, SHK, AL, AM, SR, JS,
ST, MT) who participated in the 2012 consensus
meeting. All were leading abdominal radiologists
and members of ESGAR with recognised expertise
and a publication track record within the field of rec-
tal cancer imaging. The panel also included two non-
voting Chairs (LB, RB) and three non-voting
organising members (DL, MM, SB).
Step 4 Questionnaire completion before the face-to-face
meeting
Questionnaires were emailed to panellists on 11
May 2016. Panellists rated items independently with
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no interaction amongst each other and returned com-
pleted questionnaires by email.
Step 5 Data analysis from questionnaire round
For each rated item from the electronic question-
naire round, two non-voting members (DL,MM)
assessed whether or not consensus (defined as ≥ 80
% agreement) was reached.
Step 6 Face-to-face panel meeting
A face-to-face panel meeting took place during the
annual ESGAR meeting, Prague, 15 June 2016.
Twelve of the 14 panellists attended. The meeting
was moderated by two non-voting Chairs, RB and
LB. Two non-contributing (non-voting) observers
(DL, MM) documented key points of discussion
and outcomes from the voting rounds. The results
from the electronic questionnaire round formed the
basis for discussion. Discussion included all items
from the part A questionnaire selected for re-
discussion by at least 20 % of the panellists in addi-
tion to all items from questionnaire part B that failed
to reach consensus after the email round. Some items
were rephrased or merged after face-to-face panel
discussion (to reduce ambiguity or overlap) and as a
result seven previously included items were
discarded. After each item was discussed, panellists
were asked to vote (using the same scoring systems
as in the electronic round). Thirty items were not
discussed face-to-face due to time constraints and
were voted on by email subsequently.
Step 7 Data analysis and reporting
Data from both electronic and face-to-face rounds
were collected and descriptive metrics calculated by
DL and MM. Each item was ultimately classified as:
(1) ‘Appropriate’ with ≥ 80 % agreement, (2)’
Inappropriate’ with ≥ 80 % agreement or (3;
Uncertain (no consensus, i.e. < 80 % agreement).
Results
Demographic data of the panellists’ hospitals and MRI tech-
niques are summarised in Table 1. A total of 246 items was
voted on during the electronic and/or face-to-face rounds (236
items from the original 2012 questionnaires + 17 new items –
7 discarded/merged items). A complete overview of the results
from the consensus procedure is provided in Appendix I in the
Electronic Supplementary Material (ESM).
Areas of consensus
Consensus was reached for 226/246 (92%) items. A summary
of the recommendations based on decisions reached by the
panel is given in Table 2. An overview of the main changes
and additions to the 2012 consensus paper is provided in
Table 3. In Table 4, advised criteria for nodal staging are
provided. An example of a template for structured reporting
as advised by the panel is given in Fig. 1.
Areas lacking consensus
In 20/246 (8 %) items no consensus was reached by the panel.
The items that did not reach consensus are listed in Table 5.
Main items were patient preparation, use and performance of
diffusion-weighted MRI and the diagnostic performance of
T2-weighted MRI in the restaging setting.
The panel ultimately achieved consensus for 92% of the
individual items discussed, which is comparable to outcomes
from the 2012 meeting where the figure was 88 % [1].
Although consensus was not achieved in 20/246 (8 %) items,
reasonable agreement (> 60 %) was still reached in 14 out of
these 20 items.
Imaging techniques
Consistent with the 2012 results, the panel reached consensus
that MR imaging is mandatory and the technique of first choice
for both primary staging and restaging of rectal cancer, with the
exception of staging for early tumours considered for local
excision. In these cases patients should be referred for
(additional) endorectal ultrasound (EUS), given its superior
diagnostic performance for differentiating T1 from T2 tumours
[8, 9]. Additionally, the panel agreed that when considering
organ-preservation (‘watchful waiting’) as a treatment option
after chemoradiotherapy, it is mandatory to correlate the
restagingMRI findings with clinical examination (digital rectal
examination and endoscopy) as this combination has been
shown to be most accurate when establishing a correct diagno-
sis of complete response [10]. The best timing to perform the
restaging MRI (i.e. how many weeks after completion of CRT)
is an issue of ongoing debate, but there is evidence suggesting
that longer waiting intervals may increase response rates [11,
12]. In recently published reports that routinely included MRI
to select patients for organ-preservation, a waiting interval of
around 8 weeks was typically employed [2, 3].
Patient preparation
As for 2012, no consensus was reached regarding the use of
spasmolytics (e.g. Buscopan® or Glucagon) or endorectal
filling. Routine spasmolytics were advised by 57 % of the
panel (compared to 50 % in 2012) and endorectal filling by
29 % (17 % in 2012). Panellists that apply spasmolytics sug-
gested that it can be particularly beneficial for upper rectal
tumours and when imaging is performed at 3.0T, because in
these cases bowel movement artefacts are most prevalent.
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Regarding endorectal filling, the panel noted that it can be
useful in specific cases, particularly to reduce susceptibility
artefacts related to luminal gas during diffusion-weighted
MRI. The increased use of DWI in current practice may there-
fore explain the increased recommendation for endorectal fill-
ing by the panel compared to 2012. However, its use was not
recommended routinely, mainly because rectal wall distension
may interfere with interpretation of the distance between the
tumour and the mesorectal fascia [13]. When choosing to fil
the rectum nonetheless, the panel therefore suggests using a
volume of only approximately 60 ml of gel, since higher vol-
umes will compress perirectal tissues significantly [14].
Another potential drawback of rectal gel filling is that the high
T2 signal of the gel may cause T2 shine through effects on
DWI. A potential alternative currently being investigated is
the use of a micro-enema to reduce the amount of luminal
gas. This option will need further exploration as results are
presently only single centre [15, 16].
Criteria for MR imaging assessment
The 2012 meeting reached consensus for the majority of im-
aging criteria discussed. The majority of debate revolved
around which criteria should be used for nodal staging. In
2012 the panel agreed that no single size threshold was suffi-
ciently accurate to differentiate benign from metastatic nodes.
Furthermore, it was agreed with 70–75 % consensus that ad-
ditional morphological criteria (shape, border, signal hetero-
geneity) can be beneficial to help characterisation. The 2016
panel agreed that, despite the fact that nodal staging remains
challenging with well-known inaccuracies, it would be desir-
able to at least offer a practical guideline incorporating both
Table 1 Demographic data and
MRI techniques of the panellists'
base hospitals
Median (range) number of patients diagnosed with rectal cancer per year 110 (30–300)
MRI used as a standard staging technique for rectal cancer 100 %
Restaging after chemoradiation performed routinely 86 %
MR vendors*
Siemens 57 %
Philips 21 %
GE 21 %
Unknown 29 %
Field strength
1.5T 50 %
3.0T 7 %
1.5T and 3.0T 43 %
Use of a surface coil 100 %
Use of an endorectal coil 0 %
Routine use of spasmolytics (buscopan or glucagon) 43 %
Routine use of endorectal filling 29 %
Routine use of rectal (micro-)enema 14 %
Routine use of intravenous contrast material 29 %^
Diffusion-weighted MRI part of routine rectal MRI protocol 93 %
Dynamic contrast enhanced MRI part of routine rectal MRI protocol 29 %
Version of Tumour Node Metastases (TNM) staging system used
TNM 5 7 %
TNM 6 0 %
TNM 7 86 %
unknown 7 %
Organ-preservation offered as a treatment option after chemoradiotherapy
No 29 %
only local excision 21 %
only watchful waiting 7 %
both (local excision and watchful waiting) 43 %
MRI used as a follow-up modality (in centers performing organ preservation) 100 %
*21 % use multiple vendors
^ In the four centers routinely applying intravenous contrast it is used for DCE in 3/4 and for nodal staging in 1/4
cases
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size and morphology. This resulted in the criteria described in
Table 4, which were based on criteria described in Dutch
evidence-based guidelines on rectal cancer treatment [17].
The main aim of this approach was to establish more stringent
criteria and thereby increase the threshold so as to avoid over-
calling nodes as malignant. The literature suggests around 25
% of nodes are overstaged [8], which could mean unnecessary
preoperative treatment and associated short-term (e.g.
Table 2 Synopsis and key recommendations (based on items for which ≥ 80 % consensus was reached)
I - Recommendations for MR image acquisition
a. hardware
MRI should routinely be performed for primary staging and restaging of rectal cancer
Endorectal ultrasound is the preferred technique for the differentiation and staging of T1 tumours
MRI should be performed with an external surface coil on a 1.5T or 3.0T MRI system
b. patient preparation
Use of an enema is not routinely recommended
(Use of spasmolytics may be useful to reduce bowel movement artefacts (no consensus: 57 % recommended/mandatory))
(Use of endorectal filling is not routinely advised (no consensus: 71 % not recommended))
c. sequences and sequence angulation
A routine protocol should (at least) include 2D T2-weighted sequences in 3 planes and a diffusion-weighted sequence
(including at least a high b-value of ≥ 800)
Diffusion-weighted images (including Apparent Diffusien Coefficient maps) should mainly be assessed visually;
quantitative ADC measurements are not routinely advised
Diffusion-weighted imaging is recommended for restaging of the yT-stage.
Fatsuppressed, T1-weighted (non-enhanced and contrast-enhanced) and dynamic contrast enhanced (DCE) sequences are not routinely recommended
Slice thickness (for the axial and coronal T2-weighted sequences) should be ≤ 3 mm
Transverse and coronal sequences should be angulated perpendicular and parallel to the rectal tumour axis, respectively.
In distal tumours a coronal sequence angulated parallel to the anal canal should be included to assess the relation between tumour and anal sphincter
II - Recommendations for MR image evaluation and reporting
a. primary staging
Structured reporting is recommended and should include the items described in the report template in Fig. 1
For nodal staging the criteria described in Table 4 are recommended
Stranding into the mesorectal fat is an equivocal sign that may indicate either a T2 or T3 tumour
The mesorectal fascia (MRF) is 'involved' if the distance between MRF and tumour is ≤1 mm
When a tumour shows stranding into the MRF, the MRF should be considered involved
A tumour that involves the MRF should be considered a T3 (and not a T4) tumour
Tumour invasion above the level of the peritoneal reflection (at the anterior side) should be considered at risk for peritoneal rather than MRF invasion
A tumour that invades the pelvic floor or pelvic side wall muscles should be considered a T4 tumour
A tumour that grows into the internal anal sphincter muscle should be considered a T3 (and not a T4) tumour
b. restaging after neoadjuvant treatment
Structured reporting is recommended and should include the items described in the report template in Fig. 1
For nodal restaging the criteria described in Table 4 are recommended
On T2-weighted MRI, a normalised, two-layered wall after CRT is suggestive of a complete response
On T2-weighted MRI, a completely hypointense (fibrotic) residue without an isointense mass indicates a complete or near-complete response
When considering organ preservation (watchful waiting) after CRT, MRI findings should be correlated with clinical examination
(endoscopy / digital rectal examination)
If a fatpad re-appears between the tumour and MRF after CRT, the MRF should be considered uninvolved/cleared.
Persistent stranding of tumour into the MRF should be considered an equivocal sign that may or may not indicate persistent MRF involvement
III - MRI performance
a. T2-weighted MRI
Primary staging
2D T2-weighted MRI can be used to reliably (≥80 % accurate):
Differentiate between T2 and T3 tumours
Differentiate between non-involved and involved mesorectal fascia
2D T2-weighted MRI is not accurate to differentiate between T1 and T2 tumours
b. Diffusion-weighted MRI
Primary staging
Diffusion-weighted MRI is not accurate to:
differentiate between T1 and T2 tumours
differentiate between T2 and T3 tumours
differentiate between N0 and N+ stage
differentiate between non-involved and involved mesorectal fascia
assess EMVI
Restaging
Diffusion-weighted MRI is not accurate to:
differentiate between T1 and T2 tumours
differentiate between N0 and N+ stage
assess EMVI
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proctitis) and long-term (e.g. faecal incontinence, bowel and
urogenital dysfunction) morbidity [18]. It has even been sug-
gested that nodal staging by imaging should be discarded
altogether, because of known staging inaccuracies and be-
cause it has been suggested that patients with ‘good prognos-
tic’ tumours (defined on MRI as ≤cT3b stage without MRF
involvement) have good outcomes regarding survival and lo-
cal recurrence rates, irrespective of nodal stage [19]. However,
this strategy has not been adopted widely and nodal stage as
determined by imaging, despite proven inaccuracies, is still
believed to be an important treatment determinant and includ-
ed inmost current guidelines [18–20]. Another point of debate
was whether or not the criteria described in Table 4 are also
applicable to extramesorectal (obturator and iliac) nodes.
There is to date no solid evidence regarding specific or alter-
native (size) criteria for extramesorectal nodes and as such it
was not deemed feasible to recommend any specific criteria
for these nodes. Therefore the panel agreed that, from a prac-
tical point of view, the same criteria recommended for the
mesorectal lymph nodes (Table 4) may for now also be used
for these extramesorectal nodal stations.
Another addition to the 2012 guideline was the use of T-
substages such as T3a,b,c,d (which categorise tumours via
differing depths of extramural invasion). Also, discussion
around the definition of T3 versus T4 stage in various settings
was added. The problem with these definitions is that they can
depend on the TNM version used, which may vary between
and even within centres, precipitating confusion. For example,
thepanelcouldnotagreeunanimously(93%consensus)whether
a tumour invading themesorectal fasciawasT3orT4. Similarly,
the panel could not reach consensuswhether a tumour involving
the external anal sphincter shouldbeT3 (29%of thepanel) orT4
(71 %). To avoid confusion, the panel agreed that, regardless of
the TNM version employed, the main aim should be to provide
theclinicianwithanMRreport that includesanddescribesclearly
all relevant information needed for treatment planning, rather
than to focus on terminology. For example, for low tumours
involving the anal sphincter complex, it is pertinent to describe:
(a)whether the tumour invadesonly the internal sphinctermuscle
or also involves the intersphincteric plane andexternal sphincter,
(b) whether sphincter invasion involves only the proximal one-
thirdof thecomplexorextendsinto themiddleand/or lower third,
and (c)whether the pelvic floor (levator) is involved. Such infor-
mation is pivotal when deciding the surgical approach, e.g.
whether or not sphincter-saving resection is feasible without
compromising local control. In such cases, accurate anatomical
description of local extent provides more relevant information
than the T-stage alone.
MRI reporting
In addition to the MR imaging criteria described above, the
panel agreed that description of tumour location in relation to
the anterior peritoneal reflection should be reported as an extra
Table 4 Practical guidelines for nodal staging
Primary staging
Criteria for malignant node:
1. Short axis diameter ≥ 9 mm
2. Short axis diameter 5–8 mm AND ≥ 2 morphologically
suspicious characteristics*
3. Short axis diameter < 5 mm AND 3 morphologically
suspicous characteristics*
4. All mucinous lymph nodes (any size)
* Morphologically suspicious criteria:
Round shape
Irregular border
Heterogeneous signal
Restaging (after long course neoadjuvant treatment + downstaging
interval)
All nodes with a short axis diameter < 5 mm should be considered
benign
For nodes with a short axis diameter ≥ 5 mm no reliable criteria exist.
As a practical guideline these nodes should be considered malignant.
NB. These criteria should only be applied using high-resolution (≤ 3 mm
slice thickness) transverse images.
NB2. These criteria specifically apply to nodes within the mesorectal
compartment, but may also be adopted for other regional extramesorectal
(i.e. obturator and iliac) nodes
NB3. The criteria described above are intended as a practical guideline.
The panel acknowledges known inaccuracies of MRI for nodal staging.
Table 3 Main changes and additions to the 2012 consensus meeting
results
Main changes
Slice thickness should be ≤ 3 mm (recommended slice
thickness ≤ 4 mm in 2012)
The circumferential location of the tumour within the rectal wall
(e.g. from X to X o'clock) should routinely be reported
(no consensus in 2012)
EMVI should routinely be reported at primary staging as well as at
restaging after CRT (no consensus on reporting of EMVI
after CRT in 2012)
Main additions
Recommendation to report T3 substages (T3a,b,c,d)
and T4 substages (T4a,b)
Recommendation to perform structured reporting
(example of structured reporting template is provided in Fig. 1)
Specified criteria for nodal staging (see Table 4)
Specified definitions for T3 versus T4 tumours in case of sphincter
invasion, MRF, pelvic wall/floor involvement and for tumours
below or at/above the level of the anterior peritoneal reflection
Specified indications for DWI
Specified minimal requirements for DWI (protocol should include at
least a high b-value of ≥ b800; assessment should consist of visual
evaluation of DW images and ADC-map, quantification of ADC is
not routinely recommended)
Eur Radiol (2018) 28:1465–14751470
Local tumour status
- Morphology: Solid - polypoid
Solid - (semi-)annular: from ........ to ....... o’clock
Mucinous: from ........ to ....... o’clock 
- Distance from the anorectal junction to the lower pole of the tumour: ……………… cm
- Tumour length: ………………. cm   
- T-stage: T1-2
T3 T3a or T3b (≤5 mm extramural growth)
T3c or T3d (>5 mm extramural growth)
T4, based on growth into: ……………………………
- Sphincter invasion:        No
Internal sphincter only
“ + intersphincteric plane
“ + external sphincter
Mesorectal fascia (and peritoneal) involvement
- Shortest distance between tumour and MRF: ……. mm free (> 2 mm)
threatened/involved (≤2 mm)
- Location of the shortest distance between tumour and MRF: ………. o’clock
- Relation to anterior peritoneal reflection:        below (MRF invasion) above
Lymph nodes and tumour deposits
- N-stage:              N0                  N+  
- Total number of lymph nodes: ………………
- Number of suspicious lymph nodes: ………………..   (….. mesorectal nodes; ….. extramesorectal nodes)
….. nodes with short axis diameter ≥ 9 mm
….. nodes with short axis diameter 5-8 mm AND at least 2 morphologic criteria*
….. nodes with short axis diameter < 5 mm AND all 3 morphologic criteria* 
*N.B. Morphologic suspicious criteria: [1] round shape, [2] irregular border, [3] heterogenous signal
- Are there any tumour deposits within the mesorectum:         no, 
yes, ….. (number of deposits)
Extramural vascular invasion
Yes No
Structured MRI report template
primary staging
upper middle distal 1/3 of anal canal
Fig. 1 Template for structured MRI report for primary staging and restaging after chemoradiation
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Local tumour status
- Residual tumour mass: No, completely normalised rectal wall (complete response)
No, fibrotic wall thickening without clear residual mass (complete or near 
complete response)
Yes, residual mass (and/or focal high signal on DWI):
yT-stage: yT1-2
yT3 yT3a or yT3b (≤5 mm extramural growth)
yT3c or yT3d (>5 mm extramural growth)
yT4, based on growth into: ……………………………
- Distance from the anorectal junction to the lower pole of the tumour: ……………… cm
- Tumour length: ………………. cm 
- Sphincter invasion: No
Internal sphincter only
“ + intersphincteric plane
“ + external sphincter
Mesorectal fascia (and peritoneal) involvement
- Shortest distance between tumour and MRF: ……. mm free (> 2 mm)
threatened/involved (≤2 mm)
- Location of the shortest distance between tumour and MRF: ………. o’clock
- Relation to anterior peritoneal reflection:        below (MRF invasion)         above  
Lymph nodes and tumour deposits
- Lymph nodes                      yN0 = no remaining nodes or only nodes < 5 mm
yN+, = presence of any nodes with a short axis diameter ≥ 5 mm
- Number of residual suspicious (≥ 5 mm) mesorectal lymph nodes: …………………….
- Number of residual suspicious (≥ 5 mm) extramesorectal lymph nodes: …………………….
- Are there any remaining tumour deposits within the mesorectum:         no 
yes, ….. (number of deposits)
Extramural vascular invasion
Yes No
Structured MRI report template
restaging after neoadjuvant treatment
upper middle distal 1/3 of anal canal
Fig. 1 (continued)
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item (omitted from the 2012 guidelines). This item was added
as it can be a potential source of confusion: The anterior peri-
toneal reflection is a landmark that is usually recognised easily
on MRI and separates the intra- and extra-peritoneal portions
of the mesorectal compartment [20]. Above the anterior peri-
toneal reflection, the mesorectal compartment is no longer
enveloped by the mesorectal fascia on its anterior aspect. As
such, anterior mesorectal fascia involvement should only be
reported when below the level of the anterior peritoneal
reflection.
Another important addition to the 2012 guideline is a rec-
ommendation for structured reporting. A structured report
template has been suggested previously and published online
by the Radiological Society of North America (RSNA;
radreport.org). In Fig. 1 we propose an alternative template
(both for primary staging and for restaging after neoadjuvant
treatment) based on the specific recommendations arising
from this 2016 updated consensus meeting. Studies have
shown that implementation of structured report templates
can improve the quality of MRI reporting for rectal cancer
staging compared to free-text formats, and leads to higher
satisfaction levels from referring surgeons [21, 22].
Accordingly, structured reporting is now recommended by
the panel unanimously. The structured report (see Fig. 1) in-
cludes measurement of tumour longitudinal extent. This, how-
ever, was an item that was debated face-to-face. Although the
panel agreed unanimously that ‘somemeasure of tumour size’
should be reported, there was no clear consensus on a specific
metric, i.e. whether this should be one-dimensional, three-
dimensional or a volume measurement, and if and how after
CRT an estimation of the tumour volume reduction should be
provided. There is no solid evidence that favours one over
another, although some authors have suggested that, specifi-
cally for assessment of chemoradiotherapeutic response,
whole volume measurements may be preferable [23]. The
panel acknowledges that several options exist but from a prac-
tical point of view decided to include tumour length as the
main metric in the structured report template in Fig. 1, as this
was deemed to be most commonly used and more practically
applicable than other metrics, with good reported measure-
ment reproducibility [20, 23, 24].
Finally, the panel agreed that assessment of extramural
vascular (or venous) invasion (EMVI) should be reported rou-
tinely, both for primary staging as well as for restaging after
CRT. In 2012, reporting of EMVI after CRT was not advised
unanimously. This change is likely the result of emerging
evidence supporting EMVI as an important prognostic staging
factor [25–27].
Diffusion-weighted imaging and dynamic
contrast-enhanced MRI
Since publication of the previous ESGAR consensus
guidelines in 2013, numerous reports have emerged inves-
tigating use of functional imaging techniques for rectal
cancer (re)staging, of which DWI and dynamic contrast-
enhanced MRI have been researched most extensively. As
such, the panel decided to specifically address whether
these techniques should be incorporated into routine pro-
tocols and, if so, in which circumstances. In concordance
Table 5 Items lacking consensus
Patient preparation
Use of spasmolytics (recommended by 57 % of the panel)
Use of endorectal filling (recommended by 29 % of the panel)
Diffusion-weighted imaging
There was no consensus on the number of b-values required
(57 % consensus at least 2; 43 % consensus at least 3)
There was no consensus on whether DWI should be used for:
assessment of T-stage at primary staging (31 % not recommended;
46 % unsure*; 8 % recommended; 15 % mandatory)
assessment of N-stage at primary staging (23 % not recommended;
38 % unsure*; 31 % recommended; 8 % mandatory)
assessment of yN-stage at restaging (15 % not recommended; 31 %
unsure*; 23 % recommended; 23 % mandatory)
assessment of MRF at restaging (15 % not recommended; 62 %
unsure*; 15 % recommended; 8 % mandatory)
MRI performance
There was no consensus whether 2D T2-weighted MRI is reliable
(≥ 80 % accurate) to:
differentiate between N0 and N+ stage at primary staging
(not reliable with 69 % consensus)
assess EMVI at primary staging (reliable with 69 % consensus)
differentiate between a complete response and residual tumour at
restaging (not reliable with 69 % consensus)
differentiate between yT1-2 and yT3-4 tumours at restaging after
CRT (reliable with 62 % consensus)
differentiate between yN0 and yN+ stage at restaging after CRT
(reliable with 62 % consensus)
differentiate between non-involved and involved MRF at restaging
after CRT (reliable with 62 % consensus)
assess EMVI at restaging after CRT (reliable with 54 % consensus)
There was no consensus whether diffusion-weighted MRI is reliable
(≥ 80 % accurate) to:
differentiate between a complete response and residual tumour at
restaging (reliable with 54 % consensus)
differentiate between yT1-2 and yT3-4 tumours at restaging after
CRT (not reliable with 69 % consensus)
differentiate between non-involved and involved MRF at restaging
after CRT (not reliable with 69 % consensus)
MRI reporting
reporting of N-substages (N1a, N1b) (recommended by 31 % of the
panel)
There was no consensus whether a tumour that invades the external
anal sphincter should be considered a T3 (29 % consensus) or T4
(71 % consensus) tumour
*Unsure indicates that it is not routinely recommended, but may be useful
for particular cases
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with the 2012 recommendations, the panel agreed that
diffusion-weighted MRI should be performed routinely,
in particular for restaging to evaluate response (the yT-
stage) to chemoradiotherapy. This decision reflects the
increasing volume of data reporting that DWI can im-
prove the performance of MRI for T-restaging after neo-
adjuvant treatment, specifically for differentiation be-
tween complete and partial response [28–32]. Although
85 % of the panel recommended using DWI to assess
yT-stage after CRT, only 54 % believed that DWI alone
is able to identify patients with complete response reli-
ably. The panel recognises that findings from both T2-
weighted MRI and DWI will need to be combined with
digital rectal examination and endoscopy to obtain the
most accurate diagnosis when aiming to identify complete
responders for organ-preserving treatment strategies [10].
For all other indications (primary T-staging, (y)N-staging,
assessment of MRF involvement and EMVI) the panel
either reached consensus or the majority of panellists
agreed (achieving 54–77 % consensus) that there is no
clear added benefit for DWI based on current evidence,
although several panellists did point out that DWI may be
of value for individual cases. Furthermore, the panel
agreed unanimously that diffusion-weighted images (and
ADC maps) should be assessed qualitatively, with no cur-
rent role for quantification of ADC in daily practice due
to a lack of standardised protocols and validated thresh-
olds. Regarding DCE-MRI, the panel reached full consen-
sus that, although some promising data are available
[33–37], it should currently be considered as a research
tool and not be adopted routinely. Nevertheless, panellists
again acknowledged that DCE may be useful for individ-
ual cases, particularly to improve tumour conspicuity after
neoadjuvant treatment and for assessment of mucinous
tumours.
Methodological limitations
Our consensus process has some limitations. Two panellists
were absent during the face-to-face meeting. For items
discussed and voted upon during this meeting, we therefore
calculated the percentage of agreement based on those
panellists present. As for the 2012 version, our recommenda-
tions concern predominantly the staging of non-mucinous ad-
enocarcinomas. No specific recommendations regarding as-
sessment of mucinous tumours (except for mucinous lymph
nodes described in Table 4) weremade. Although unavoidable
for face-to-face methodology, bias might be introduced by
undue influence from those panellists with ‘dominant’ person-
alities. We attempted to counter this via non-voting Chairs
who ensured that discussions were well-balanced. Finally,
the panel is selected and thus may not be fully representative
of all opinions.
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